Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-456-9 | CAS number: 3102-70-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In this experiment the test item was examined for acute toxicity after oral administration to rats. Dose levels of 300 or 2000 mg/kg b.w. were employed. The LD50value was ranked between 300 and 2000 mg/kg b.w., by oral administration (LPT, 2016).
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2016-03-17 to 2016-05-25
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Version / remarks:
- (2008)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- (2001)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
- Species:
- rat
- Strain:
- other: CD / Crl: CD(SD)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, 97633 Sulzfeld, Germany
- Age at start of administration: Approx. 8 weeks
- Weight at start of administration: 178 - 185 g
- Fasting period before study: approx. 16 hours
- Housing: During the 14-day observation period the animals were kept in groups of 3 animals in MAKROLON cages (type III plus). Granulated
textured wood was used as bedding material for the cages.
- Diet:Commercial diet, ssniff® R/M-H V1534 (Certificates of analysis provided) ; discontinued approx. 16 hours before administration
- Water: tap water ad libitum
- Acclimation period: At least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C):22°C ± 3°C
- Humidity (%): 55% ± 15%
- Air changes (per hr): 12 to 18-fold air change per hour
- Photoperiod (hrs dark / hrs light): 12 hrs dark/12 hrs light (about 150 lux at approx. 1.50 m room height) - Route of administration:
- oral: gavage
- Vehicle:
- other: 0.8% aqueous hydroxypropylmethylcellulose
- Details on oral exposure:
- Vehicle: 0.8% aqueous hydroxypropylmethylcellulose
Route of administration Oral, by gavage
Selection of route of administration According to the OECD/EC guidelines
Vehicle 0.8% aqueous hydroxypropylmethylcellulose
Administration volume 10 mL/kg b.w.
Dose levels 300 and 2000 mg/kg b.w.
CLASS METHOD (if applicable)
Principle of the ATC-test method
This procedure permits the identification of the 'acute-toxic-class' (ATC), a measure-ment of the acute toxicity by the oral route.
The test item is administered orally by gavage at a single dose level to a group of experimental animals. The dose used is selected from a series of defined dose levels. Due to the small number of animals used with this method, there is no need to perform a range finding test.
The test item is tested using a stepwise procedure, each step uses three female animals. The results of each step determine if:
o no further testing is needed,
o the next step will be performed with the same dose,
o the next step will be performed at the next higher or next lower dose level.
Starting at 2000 mg/kg b.w.
If, in this second step, two to three animals die, testing at 300 mg/kg b.w. should be performed. If, in this second step, no to one animal dies, no further testing is necessary.
Testing at 300 mg/kg b.w.:
Three female animals are treated at 300 mg/kg b.w. (first step).
If fewer than two animals die, the test item should be retested (second step) with 300 mg/kg b.w., using three animals of the same sex. - Doses:
- 300 and 2000 mg/kg b.w.
- No. of animals per sex per dose:
- 3 female animals 2000 mg/kg b.w.
6 female animals 300 mg/kg b.w. - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations were performed before and immediately, 5, 15, 30 and 60 min, as well as 3, 6 and 24 hours
after administration. All surviving animals were observed for a period of 14 days. Individual body weights were recorded before administration
of the testsubstance and thereafter in weekly intervals up to the end of the study.
- Necropsy of survivors performed: At the end of the experiments, all animals were sacrificed, dissected and inspected macroscopically. All gross
pathological changes were recorded.
- Other examinations performed: changes of skin and fur, eyes and mucous membranes, respiratory and the circulatory,autonomic and central
nervous system and somatomotor activity as well as behaviour pattern were observed at least once a day until all symptoms subsided, thereafter
each working day. Any tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma were also noted. - Statistics:
- No statistical analysis was performed as the method used is not intended to allow a calculation of a precise LD50 value.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 300 - < 2 000 mg/kg bw
- Mortality:
- Under the present test conditions, oral administration of 2000 mg test item/kg b.w. revealed lateral position in all 3 of three animals. All 3 animals died within 24 hours after administration
- Clinical signs:
- other: Oral administration of 300 mg test item/kg b.w. revealed slightly reduced motilitly, slight ataxia, slightly reduced muscle tone, slight dyspnoea in all 6 of 6 animals, closed eyes in 5 of 6 animals and dorsal position in 1 of 6 animals. One animal died w
- Gross pathology:
- No pathological changes were observed at necropsy.
- Other findings:
- - Histopathology:
No histopathology was carried out as no macroscopical findings were noted at autopsy. - Conclusions:
- The LD50 value was ranked between 300 and 2000 mg/kg b.w.
- Executive summary:
In this experiment the test item was examined for acute toxicity after oral administration to rats. Dose levels of 300 or 2000 mg/kg b.w. were employed.
Under the present test conditions, oral administration of 2000 mg test item/kg b.w. revealed lateral position in all 3 of three animals. All 3 animals died within 24 hours after administration.
Oral administration of 300 mg test item/kg b.w. revealed slightly reduced motilitly, slight ataxia, slightly reduced muscle tone, slight dyspnoea in all 6 of 6 animals, closed eyes in 5 of 6 animals and dorsal position in 1 of 6 animals. One animal died within 7 days after administration.
All surviving animals gained the expected weight at the end of the study period.
No pathological changes were observed at necropsy.
The LD50value was ranked between 300 and 2000 mg/kg b.w., by oral administration.
Test item
LD50[mg/kg b.w., oral]
females
300 - 2000
Reference
no further information
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Quality of whole database:
- The study is valid without restriction (Klimisch 1).
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
Based on the results of the acute oral study and according to the Globally Harmonized Classification System (GHS) the test item is classified in the hazard category 4, required labelling with 'Warning' and 'Harmful if swallowed'. According to the EC Regulation 1272/2008 and subsequent regulations, the test item required labelling with 'Warning' and 'H302: Harmful if swallowed'.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.